AIDS Vaccine Science for Busy Advocates – Passive Immunization: An important piece of the puzzle

A one-page document describing passive immunization, the transfer of pre-made antibodies, and its potential for HIV prevention.

HIV Vaccines: Key messages

This is a three-page document providing main points surrounding vaccine research. For a shorter one-page version of this, click here.

Pre-Exposure Prophylaxis: An introductory factsheet

This introductory 2-page document defines PrEP, reviews the scientific evidence to date, and outlines key research, regulatory and advocacy issues going forward. This factsheet is part of a series on emerging HIV prevention strategies.

Treatment as Prevention: An introductory factsheet

This introductory 2-page document defines treatment as prevention, reviews the scientific evidence behind it, and outlines implementation advocacy priorities. The factsheet is part of a series on emerging HIV prevention strategies.

Microbicides for HIV Prevention: An introductory factsheet

This introductory 2-page document defines microbicides and reviews the state of research on some leading candidates.

Multipurpose Prevention Technologies (MPTs): An introductory factsheet

This introductory 2-page document makes the case for why women need prevention options that protect them against multiple risks—HIV, STIs and/or pregnancy—and discusses the products that are being studied for this purpose. The factsheet is part of a series on emerging HIV prevention strategies.

Women and HIV Prevention Research: Designing, testing and marketing products to improve adherence

The fourth webinar in AVAC’s Research & Reality series, a year-long dialogue about prevention research and advocacy, this webinar provided a forum to learn about and discuss key issues around women and the HIV prevention agenda, including challenges around marketing of and adherence to new prevention options. Click for speaker details, slides and audio.

2005 AVAC Report: AIDS Vaccines at the Crossroads

This year’s Report offers recommendations for the field in general, the Global HIV Vaccine Enterprise, policy makers, researchers and communities. Some of these recommendations will be familiar because AVAC has made them before, and they are reiterated because it is AVAC’s belief that they are still needed. The Report also provides an update on tenofovir pre-exposure prophylaxis research.

2004 AVAC Report: AIDS Vaccine Trials: Getting the Global House in Order

This year’s Report focuses on how the field is readying itself for the road ahead. Several chapters address different aspects of “readiness”—a term that means different things to different people, but that is at the heart of the AIDS vaccine advocacy agenda today.

Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.